Intelsat Continues Investment in Global 5G Software-Defined Network with Acquisition of Two Software-Defined Satellites from Thales Alenia Space
12.1.2022 13:00:00 EET | Business Wire | Press release
Intelsat, operator of the world’s largest integrated satellite and terrestrial network, and Thales Alenia Space, Joint Venture between Thales (67%) and Leonardo (33%) have signed an agreement to build two software-defined satellites designed to advance Intelsat’s global fabric of software-defined GEO connectivity as part of its 5G software-defined network.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220112005271/en/
The artist’s view represents the two Intelsat software-defined satellites, IS-41 and IS-44, with the corresponding antennas configuration. (courtesy: Thales Alenia Space).
The addition of the Thales Alenia Space software-defined satellites represents an essential advancement in Intelsat’s 5G software-defined network designed to enable greater agility, flexibility and orchestration across edge, satellite and core. Named Intelsat 41 (IS-41) and Intelsat 44 (IS-44), the two next-generation software-defined satellites are scheduled to be in service in 2025. They will join two Airbus constructed software-defined satellites, Intelsat 42 (IS-42) and Intelsat 43 (IS-43), announced January 8, 2021.
Intelsat 41 and Intelsat 44 will be based on the Thales Alenia Space’s innovative Space Inspire product line allowing seamless telecommunications mission and services reconfiguration, instant in-orbit adjustment to broadband connectivity demand, and superior video broadcasting performance while maximizing the effective use of the satellite resources.
“Intelsat’s standards-based, open-architecture network design facilitates the incorporation of the best technology at any given time, further bolstering network resiliency,” said Stephen Spengler, CEO of Intelsat. “With the addition of Intelsat 41 and Intelsat 44, in partnership with Thales Alenia Space, Intelsat will blanket the earth with software-defined satellites, progressing the world’s first global 5G software-defined network, designed to unify the global telecoms ecosystem.”
The contract enables the continued advancement of Intelsat’s planned global software-defined satellite-based network, adding high-speed dynamically-allocated connectivity across Africa, Europe, the Middle East and Asia for commercial and government mobility services and cellular backhaul.
“Our relationship with Intelsat has been so meaningful knowing that our attractive Space Inspire software-defined solution will contribute to the realization of Intelsat’s global 5G software-defined unified network,” said Hervé Derrey, CEO of Thales Alenia Space. “We are proud that our advanced satellite technology will play a significant role in Intelsat’s vision to reimagine the global telecoms ecosystem.”
About Intelsat
As the foundational architects of satellite technology, Intelsat operates the world’s most trusted satellite telecom network. We apply our unparalleled expertise and global scale to connect people, businesses, governments and communities, no matter how difficult the challenge. Intelsat is building the future of global communications with the world’s first hybrid, multi-orbit, software-defined 5G network designed for simple, seamless, and secure coverage precisely when and where our customers most need it. Follow the leader in global connectivity and “Imagine Here,” with us, at Intelsat.com .
About Thales Alenia Space
Drawing on over 40 years of experience and a unique combination of skills, expertise and cultures, Thales Alenia Space delivers cost-effective solutions for telecommunications, navigation, Earth observation, environmental management, exploration, science and orbital infrastructures. Governments and private industry alike count on Thales Alenia Space to design satellite-based systems that provide anytime, anywhere connections and positioning, monitor our planet, enhance management of its resources, and explore our Solar System and beyond. Thales Alenia Space sees space as a new horizon, helping to build a better, more sustainable life on Earth. A joint venture between Thales (67%) and Leonardo (33%), Thales Alenia Space also teams up with Telespazio to form the parent companies’ Space Alliance, which offers a complete range of services.
Thales Alenia Space has around 7,700 employees in 10 countries with 17 sites in Europe and a plant in the U.S. www.thalesaleniaspace.com .
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220112005271/en/
Contact information
Melissa Longo, Intelsat, +1 (240) 308-1881, melissa.longo@intelsat.com
Thales Alenia Space contact(s)
Sandrine Bielecki, +33 (0)4 92 92 70 94, sandrine.bielecki@thalesaleniaspace.com
Catherine des Arcis, +33 (0)6 78 64 63 97, catherine.des-arcis@thalesaleniaspace.com
Marija Kovac, +39 (0)6 415 129 91, marija.kovac-somministrato@thalesaleniaspace.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 17:00:00 EEST | Press release
PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 16:53:00 EEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release
Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release
Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom